Apolipoprotein biopolymer markers predictive of alzheimers disease
OwnerGeorge Jackowski, John Marshallinventors
Life of this patent
Estimating the term…
Abstract
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Claims38
A biopolymer marker selected from the group consisting of sequence ID (R)LQAEAFQAR(L), (R)ASSIIDELFQDR(F), (R)AATVGSLAGQPLQER(A), (−)KVEQAVETEPEPELR(Q), (K)LFDSDPITVTVPVEVSR(K), (K)SLAELGGHLDQQVEEFR(R), (R)EPQDTYHYLPFSLPHR(R) or at least one analyte thereof useful in indicating at least one particular disease state.
A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:
- at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group consisting of sequence ID (R)LQAEAFQAR(L), (R)ASSIIDELFQDR(F), (R)AATVGSLAGQPLQER(A), (−)KVEQAVETEPEPELR(Q), (K)LFDSDPITVTVPVEVSR(K), (K)SLAELGGHLDQQVEEFR(R), (R)EPQDTYHYLPFSLPHR(R) or at least one analyte thereof related to said disease state;
- and
- means for determining binding between said biochemical material and said biomolecule;
- whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.
Polyclonal antibodies produced against a marker sequence ID selected from the group consisting of sequence ID (R)LQAEAFQAR(L), (R)ASSIIDELFQDR(F), (R)AATVGSLAGQPLQER(A), (−)KVEQAVETEPEPELR(Q), (K)LFDSDPITVTVPVEVSR(K), (K)SLAELGGHLDQQVEEFR(R), (R)EPQDTYHYLPFSLPHR(R) or at least one analyte thereof in at least one animal host.
An antibody that specifically binds a biopolymer including a marker selected from the group consisting of sequence ID (R)LQAEAFQAR(L), (R)ASSIIDELFQDR(F), (R)AATVGSLAGQPLQER(A), (−)KVEQAVETEPEPELR(Q), (K)LFDSDPITVTVPVEVSR(K), (K)SLAELGGHLDQQVEEFR(R), (R)EPQDTYHYLPFSLPHR(R) or at least one analyte thereof.
A process for regulating a disease state by controlling the presence or absence of a biopolymer selected from the group consisting of sequence ID (R)LQAEAFQAR(L), (R)ASSIIDELFQDR(F), (R)AATVGSLAGQPLQER(A), (−)KVEQAVETEPEPELR(Q), (K)LFDSDPITVTVPVEVSR(K), (K)SLAELGGHLDQQVEEFR(R), (R)EPQDTYHYLPFSLPHR(R) or at least one analyte thereof.
Dependencies are inferred from the claim text.